• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

World First As UK Greenlights Landmark CRISPR Gene Editing Treatment

November 17, 2023 by Deborah Bloomfield

The world’s first CRISPR-based therapy has been approved by the UK medicines regulator, it was announced on Thursday. The pioneering treatment, which involves the much-lauded gene-editing method CRISPR, will target two blood conditions: sickle-cell disease and beta-thalassemia.

“This is a landmark approval which opens the door for further applications of CRISPR therapies in the future for the potential cure of many genetic diseases,” Kay Davies, a professor of anatomy at the University of Oxford, told the Science Media Centre.

Advertisement

According to an announcement from the medicine’s manufacturers, Vertex Pharmaceuticals and CRISPR Therapeutics, the treatment, called CASGEVY, has been authorized for certain sickle-cell disease or beta thalassemia patients aged 12 and up – around 2,000 people in the UK will be eligible to receive it.

It is thought that the US will soon follow suit, with the Food and Drug Administration expected to approve the therapy for sickle-cell patients in December and for beta-thalassemia patients next March.

Casgevy is based on the CRISPR-Cas9 gene editing system that revolutionized the field of genome engineering when its discovery was announced back in 2012. Since then, it’s been used in all manner of research, in our species and others, winning its developers a Nobel Prize in 2020.

“I am excited and a bit overwhelmed with emotion at the news of the approval of CASGEVY in the UK. Going from the lab to an approved CRISPR therapy in just 11 years is a truly remarkable achievement,” one of the system’s developers, Jennifer Doudna, said of the latest breakthrough.

Advertisement

“I am especially pleased that the first CRISPR therapy helps patients with sickle cell disease, a disease that has long been neglected by the medical establishment. This is a win for medicine and for health equity.”

Sickle-cell disease and beta-thalassemia are caused by errors in genes that code for hemoglobin – the protein in red blood cells that delivers oxygen to our tissues. 

CASGEVY makes use of the CRISPR-Cas9 system to edit a gene called BCL11A, which normally prevents production of a type of fetal hemoglobin. In doing so, it disrupts that gene, meaning the hemoglobin, which is free of the abnormalities associated with sickle-cell disease and beta-thalassemia, can be produced.

When gene-edited cells are then infused back into patients, they mature into red blood cells that contain fetal hemoglobin, and therefore boost oxygen supply to the tissues and alleviate patients’ symptoms.

Advertisement

The treatment’s approval comes off the back of promising clinical trial results, which identified no serious safety issues. However, some experts have raised potential concerns.

“It is well known that CRISPR can result in spurious genetic modifications with unknown consequences to the treated cells,” Professor David Rueda of Imperial College London told the Science Media Centre. “It would be essential to see the whole-genome sequencing data for these cells before coming to a conclusion. Nonetheless, this announcement makes me feel cautiously optimistic.”

It’s also likely to cost a lot – a price has not yet been set in the UK – which, unfortunately, will limit its reach.

“The challenge is that these therapies will be very expensive so a way of making these more accessible globally is key,” Davies added.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Soccer – FIFA backs down on threat to fine Premier clubs who play South American players
  2. U.S. House passes abortion rights bill, outlook poor in Senate
  3. Two children killed in missile strikes on Yemen’s Marib – state news agency
  4. We’ve Breached Six Of The Nine “Planetary Boundaries” For Sustaining Human Civilization

Source Link: World First As UK Greenlights Landmark CRISPR Gene Editing Treatment

Filed Under: News

Primary Sidebar

  • If Birds Are Dinosaurs, Why Are None As Big As T. Rexes?
  • Psychologists Demonstrate Illusion That Could Be Screwing Up Our Perception Of Time
  • Why Are So Many Enormous Roman Shoes Being Discovered At Hadrian’s Wall?
  • Scientists Think They’ve Pinpointed Structural Differences In Psychopaths’ Brains
  • We’ve Found Our Third-Ever Interstellar Visitor, Orcas Filmed Kissing (With Tongues) In The Wild, And Much More This Week
  • The “Eyes Of Clavius” Will Be Visible On The Moon Today, Thanks To Clair-Obscur Effect
  • Shockingly High Microplastic Levels Found On Remote Mediterranean Coral Reef Island
  • Interstellar Object, Cheesy Nightmares, And Smooching Orcas
  • World’s Largest Martian Meteorite Up For Auction Could Reach Whopping $2-4 Million
  • Kimalu The Beluga Whale Undergoes Pioneering Surgery And Becomes First Beluga To Survive General Aesthetic
  • The 1986 Soviet Space Mission That’s Never Been Repeated: Mir To Salyut And Back Again
  • Grisly Incident In Yellowstone National Park Shows Just How Dangerous This Vibrant Wilderness Can Be
  • Out Of All Greenhouse Gas Emitters On Earth, One US Organization Takes The Biscuit
  • Overly Ambitious Adder Attempts To Eat Hare 10 Times Its Mass In Gnarly Video
  • How Fast Does A Spacecraft Need To Go To Escape The Solar System?
  • President Trump’s Cuts To USAID Could Result In A “Staggering” 14 Million Avoidable Deaths By 2030
  • Dzo: Hybrids Beasts That Are Perfectly Crafted For Life On Earth’s Highest Mountains
  • “Rarest Event Ever” Had A Half-Life 1 Trillion Times Longer Than The Age Of The Universe – How Did We See It?
  • Meet The Bille, A Self-Righting Tetrahedron That Nobody Was Sure Could Exist
  • Neurogenesis Confirmed: Adult Brains Really Do Make New Hippocampal Neurons
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version